Alnylam (ALNY) Reports Q4 Profit of $1.25 EPS, Exceeds Estimates

Alnylam Pharmaceuticals Inc. (ALNY) released Q4 results showing net income of $111.5 million, or 82 cents per share, after a loss in the same period last year. Adjusted earnings were $1.25 per share, exceeding the Zacks average estimate of $1.16. Revenue of $1.1 billion missed forecasts of $1.14 billion. For the year, the company posted net income of $313.7 million, or $2.33 per share, and revenue of $3.71 billion. Shares declined 19% YTD but gained 20% over the past 12 months.